Zydus receives final approval from the USFDA for Acyclovir Capsules USP

The formulations manufacturing facility at SEZ will produce the drug for the US market

---

Ahmedabad, 29 March 2016

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Capsules USP, 200 mg. The drug falls in the anti-viral segment and will be produced at the formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.

***